title: Inflammatory breast cancer in a previously treated case of breast cancer: a diagnostic dilemma for the clinician.
abstract: Inflammatory breast cancer (IBC) is a relatively rare and aggressive subtype, accounting for nearly 2.5% of all diagnosed breast cancers worldwide. It is usually characterised by an acute onset, rapid clinical progression, poor prognosis and micrometastasis at the time of presentation. Prompt recognition of clinical symptoms and identification of warning signs are vital in diagnosing and appropriately treating a patient with IBC.
authors.affiliation: Department of Radiation Oncology, HCG Bangalore Institute of Oncology, Bangalore, Karnataka, India.
authors.forename: Rahul
authors.initials: R
authors.lastname: Ravind
authors.affiliation: Department of Radiation Oncology, HCG Bangalore Institute of Oncology, Bangalore, Karnataka, India.
authors.forename: Priyadarshini Venkatram
authors.initials: PV
authors.lastname: Kumar
authors.affiliation: Department of Radiation Oncology, HCG Bangalore Institute of Oncology, Bangalore, Karnataka, India.
authors.forename: Sasikala
authors.initials: S
authors.lastname: Prabaharan
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000628:therapy; D000069287:Capecitabine / Q000627:therapeutic use; D005260:Female; D006801:Humans; D058922:Inflammatory Breast Neoplasms / Q000175:diagnosis* / Q000188:drug therapy; D000077341:Lapatinib; D008875:Middle Aged; D016609:Neoplasms, Second Primary / Q000175:diagnosis* / Q000188:drug therapy*; D017239:Paclitaxel / Q000627:therapeutic use; D011379:Prognosis; D011799:Quinazolines / Q000627:therapeutic use
chemical_list: D011799:Quinazolines; D000077341:Lapatinib; D000069287:Capecitabine; D017239:Paclitaxel